These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28691382)

  • 1. Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies.
    Minen MT; Lindberg K; Langford A; Loder E
    Headache; 2017 Sep; 57(8):1243-1251. PubMed ID: 28691382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
    Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
    Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
    Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
    Headache; 2004; 44(7):661-8. PubMed ID: 15209687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans and migraine: advances in use, administration, formulation, and development.
    Macone AE; Perloff MD
    Expert Opin Pharmacother; 2017 Mar; 18(4):387-397. PubMed ID: 28129702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
    Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
    Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size.
    Silberstein SD; Dodick D; Kesslick J
    Headache; 2005 Oct; 45(9):1250-4. PubMed ID: 16178957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.
    Thorlund K; Mills EJ; Wu P; Ramos E; Chatterjee A; Druyts E; Goadsby PJ
    Cephalalgia; 2014 Apr; 34(4):258-67. PubMed ID: 24108308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
    Régnier SA
    Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
    Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
    Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual triptan selection in migraine attack therapy.
    Belvís R; Pagonabarraga J; Kulisevsky J
    Recent Pat CNS Drug Discov; 2009 Jan; 4(1):70-81. PubMed ID: 19149716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
    Parkinson B; Gumbie M; Cutler H; Gauld N; Mumford V; Haywood P
    Value Health; 2019 Mar; 22(3):293-302. PubMed ID: 30832967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat.
    Mullins CD; Weis KA; Perfetto EM; Subedi PR; Healey PJ
    J Manag Care Pharm; 2005 Jun; 11(5):394-402. PubMed ID: 15934798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of triptans for pediatric migraines.
    Eiland LS; Hunt MO
    Paediatr Drugs; 2010 Dec; 12(6):379-89. PubMed ID: 21028917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation Approaches of Triptans for Management of Migraine.
    Kassem AA
    Curr Drug Deliv; 2016; 13(6):882-98. PubMed ID: 27109335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.